Chief Executive Officer
CurrentBreakthrough cellular therapy company whose PBL-T™ 100% autologous anti-cancer T cells from patient peripheral blood derives from NIH-licensed technology. PBLT™ are expanded and activated using our RIV-8™ anti-T cell exhaustion protocol and then infused into the patient. This tandem process we call AUTO-T™Getting TIL (tumor-reactive T cell) from Peripheral Blood!- Two proprietary platform technologies: (1) PBL-T (Selection of tumor-reactive T cell from peripheral blood using PD1 marker) (2) RIV-8 (Reinvigoration of the exhausted T cell_ Breakthrough technology)- PBL-T is a simpler, more brilliant version of TIL (peripheral blood vs. resected lesions). - PBL-T is a process to select highly tumor-reactive T cells from a patient's peripheral blood sample based on the expression of specific T cell surface markers. After this enriched population of tumor-reactive T cells is selected and expanded to large quantities, it gets re-infused into the patient via the ACT regimen. - This technology (PBL-T) has been patented (issued) in many countries, including the US, China, Japan, the EU. - MEDGENE has robust Clinical Development Pipelines.- Two leading pipelines NCT-02 (mSTS with PBL-T) NCT-01 (mFTC with PBL-T)- RIV-8 patent has been filed and entering into the preclinical stage